Articles

EPO Sequence Listing Standards: European Patent Filing Guide

If you are filing a patent in Europe that involves biological sequences such as DNA, RNA, or amino acids, understanding the epo sequence listing standards is not optional. It is a legal and technical requirement that can make or break your patent application. The European Patent Office (EPO) has very specific rules about how sequence data must be presented, formatted, and submitted. Whether you are a biotech startup, a research institution, or a seasoned patent attorney, this guide will walk you through everything you need to know in a clear, straightforward manner.

What Are EPO Sequence Listing Standards?

The epo sequence listing standards refer to the formal rules and technical specifications that govern how biological sequences must be disclosed in a patent application filed at the European Patent Office. These standards ensure that sequence data is presented in a consistent, machine-readable format that patent offices and databases around the world can understand and process efficiently.

For many years, the EPO followed WIPO Standard ST.25 for sequence listings. However, a major transition took place on July 1, 2022, when the EPO, along with most major patent offices worldwide, officially moved to WIPO Standard ST.26. This shift was not just a technical update. It was a complete overhaul of how biological sequence information is structured, submitted, and stored.

The new epo sequence listing standards under ST.26 are based on XML (Extensible Markup Language) format, replacing the older plain-text format used under ST.25. This change brings greater precision, better data integrity, and improved interoperability with global biological databases such as GenBank, EMBL, and DDBJ.

Why the Transition to WIPO ST.26 Matters?

Understanding why the EPO moved to ST.26 helps you appreciate the depth of the epo sequence listing standards currently in place. The old ST.25 standard had significant limitations. It used a flat text format that could not adequately represent complex biological data. It also lacked clear rules for certain sequence types like modified nucleotides, non-standard amino acids, and circular sequences.

ST.26 addresses all of these shortcomings. Here is what changed and why it matters:

XML-based format: Every sequence listing must now be submitted as an XML file compliant with the WIPO ST.26 schema. This allows automated validation and reduces errors caused by manual formatting.
New sequence type coverage: ST.26 includes rules for D-amino acids, modified residues, branched sequences, and circular sequences that ST.25 could not handle properly.
Mandatory use of approved software: The EPO recommends using WIPO Sequence, the free software tool developed specifically to create ST.26-compliant XML sequence listings. This tool validates your file before submission.
No more ST.25 submissions accepted: Any new application filed at the EPO after July 1, 2022, must use the ST.26 standard. ST.25 sequence listings are no longer accepted for new filings.
Transitional provisions: Applications that were already filed before the cutoff date with ST.25 listings are generally not required to convert, but this depends on specific circumstances and the relevant EPO Guidelines.

Key Technical Requirements Under EPO Sequence Listing Standards

To comply with the current epo sequence listing standards, your XML sequence listing must meet very specific technical and content criteria. The following points summarize the most critical requirements every applicant must follow.

File format: The sequence listing must be a single XML file conforming to the WIPO ST.26 DTD (Document Type Definition) schema. No other file format is accepted.
File naming convention: The EPO requires a specific naming format. Typically, this includes the application number and a version indicator. Always check the EPO’s official filing portal (Online Filing 2.0 or EPO eOLF) for the exact naming rules at the time of submission.
Minimum sequence length: Nucleotide sequences must contain at least 10 specifically defined nucleotides. Amino acid sequences must contain at least 4 specifically defined amino acids. Shorter sequences do not need to be included in the listing but may still need to be described in the specification.
Mandatory disclosure: If your invention involves sequences that fall within the scope of ST.26, you are legally required to include them in the sequence listing. Failing to disclose sequences can result in objections or refusal of the application.
Language requirements: The sequence listing XML file itself is language-neutral in structure, but any free-text qualifiers within the file must be in the language of the proceedings before the EPO, which is typically English, French, or German.
No page numbering in the sequence listing: The sequence listing is not treated as part of the description in terms of page count. It is a separate document submitted alongside your application.

Practical Tips for Filing Compliant Sequence Listings at the EPO

Knowing the rules is one thing. Applying them correctly under real filing conditions is another. Here are practical, experience-based recommendations to help you stay compliant with epo sequence listing standards.

First, always use the latest version of WIPO Sequence software before generating your XML file. The software is updated regularly, and using an outdated version can produce a file that fails EPO validation checks.

Second, validate your XML file independently before submission. The EPO’s online filing system will flag errors, but catching them before upload saves time and avoids last-minute complications.

Third, if you are converting a PCT application that originally used ST.25 into the European regional phase and your application was filed before the July 2022 cutoff, review EPO Guidelines Rule 30 and the relevant transitional provisions carefully. The rules around conversion are nuanced.

Fourth, make sure every sequence referenced in your claims or description is properly included in the listing. Examiners cross-reference the specification with the listing during examination. Inconsistencies lead to formal objections under Rule 30 EPC.

Fifth, for divisional applications, remember that the sequence listing used in the parent application may need to be refiled. Do not assume it carries over automatically.

Conclusion

The epo sequence listing standards represent a critical layer of compliance for any biotech or life sciences patent application in Europe. With the full adoption of WIPO ST.26, the EPO has modernized how biological sequence data is handled, making the process more structured, transparent, and globally aligned. By understanding the format requirements, using the right tools, and staying updated on EPO guidelines, applicants can significantly reduce the risk of delays or rejections. Treat your sequence listing not as an administrative afterthought but as a core part of your patent strategy from day one.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.